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Measured versus Estimated Total Liver Volume to Preoperatively
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Objectives: To determine which method of liver volumetry is more accurate
in predicting a safe resection.
Background: Beforemajor or extended hepatectomy, assessment of the future
liver remnant (FLR) is crucial to reduce the risk of postoperative hepatic
insufficiency. The FLR volume is usually expressed as the ratio of FLR to
nontumorous total liver volume (TLV), which can be measured directly by
computed tomography (mTLV) or estimated (eTLV) on the basis of correlation
existing with the body surface area. To date, these 2 methods have never been
compared.
Methods: All consecutive, noncirrhotic patients who underwent resection
of 3 or more liver segments between April 2000 and April 2012 and for
whom (i) preoperative computed tomographic scans and (ii) body surface
area were available entered the study. The mTLV (calculated as TLV − tumor
volume) was compared with the eTLV (calculated as −794.41 + 1267.28 ×
body surface area) using volumetric data (cm3) and clinical outcomemeasures
(specifically, hepatic insufficiency and 90-daymortality). Definition of hepatic
insufficiency was peak postoperative serum total bilirubin level of more than
7 mg/dL or, in jaundiced patients, an increasing bilirubin level on day 5 or
thereafter.
Results: Two-hundred forty-three patients who had undergone major (n =
135) or extended (n = 108) hepatectomies met the inclusion criteria. Twenty-
eight patients (11.5%) developed hepatic insufficiency, whereas 7 patients
(2.9%) died postoperatively. Compared with the eTLV, the mTLV underesti-
mated the liver volume in 60.1% of the patients (P < 0.01). Forty-seven and
73 patients had an inadequate FLR based on mTLV and eTLV, respectively.
Portal vein occlusion (PVO) was used in 44 patients. In patients (n = 162) in
whom both methods did not evidence the need for PVO, postoperative hepatic
insufficiency and mortality were 4.9% and 0.6%, respectively. Conversely, in
patients (n = 27) in whom the eTLV but not the mTLV evidenced the need
for PVO, and thus PVO was not performed, hepatic insufficiency (22.2%;
P = 0.001) and mortality (3.7%; P = ns) were higher.
Conclusions: The use of eTLV identifies a subset of patients (∼11%) inwhom
liver volumetrywith themTLVunderestimates the risk of hepatic insufficiency.
Keywords: future liver remnant, hepatic insufficiency, liver volumetry, portal
vein embolization, portal vein occlusion
(Ann Surg 2013;258:801–807)
W ith advances in surgical technique and perioperative care, thefrontiers of liver surgery are extending continuously toward
moremajor or extended liver resections.1–3 This aggressive approach,
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however, has been associated with increased postoperative complica-
tions, in particular hepatic insufficiency,4 and mortality rates of 5% to
8% have been reported from specialized centers.5–7 Because volume
and function of the residual liver are intimately associated, it has be-
ing recognized that the preoperative determination of the future liver
remnant (FLR) volume is critical to ensure that functionally sufficient
liver parenchyma remains. Therefore, liver volumetry has become an
essential component of surgical planning.
The FLR volume is usually expressed as a ratio of FLR to
total liver volume (TLV) that, in most centers, is measured directly
by computed tomography (CT). The tumor volume is routinely sub-
tracted from the measured TLV to consider the extent of hepatic
replacement by tumor(s) that does not contribute to the functional
liver volume. However, this method of calculation has some inherent
disadvantages.8 To overcome these limitations, a method, defined as
standardized volumetry, that estimates the TLV based on the body
surface area (BSA) has been proposed8,9 and rapidly followed in
the clinical practice.7–10 Although many studies have investigated the
critical residual liver volume associated with the development of hep-
atic dysfunction or insufficiency,11–14 the clinical implications of the
method used to measure liver volumes have not been investigated. In
particular, a direct comparison between the 2 methods has never been
specifically performed. The purpose of this study was to determine
which of the 2 methods of liver volumetry, the traditional CT-based
one and the standardized one, is more accurate in predicting a safe,
major, or extended hepatic resection in noncirrhotic patients.
METHODS
All consecutive adult patients who underwent major or ex-
tended hepatectomies (ie, resection of ≥3 Couinaud segments) at
our institution from April 2000 to April 2012 were identified from a
prospectively collected hepatobiliary database. All noncirrhotic pa-
tientswere enrolled into this study,with the only exception of those for
whom (i) preoperative CT scan and (ii) anthropometric data (specifi-
cally, body weight and height) were not available for review. Standard
demographic, clinicopathological, and volumetric data were recorded
for all patients. Data collection and analysis were performed accord-
ing to the institutional guidelines conforming to the ethical standards
of the Helsinki Declaration.
Before resection, all patients underwent a standard preopera-
tive workup, including a routine clinical evaluation, determination of
the indocyanine green retention rate at 15 minutes, and a contrast-
enhanced CT scan of the thorax and abdomen. In selected cases, mag-
netic resonance imaging with liver-specific contrast agents,15 mag-
netic resonance cholangiopancreatography or direct percutaneous or
endoscopic cholangiography,16 and positron emission tomography
completed the evaluation process. All patients scheduled to undergo
trisectionectomies or right hepatectomies and those with an antici-
pated small FLR underwent CT volumetry and a subsequent portal
vein occlusion (PVO), consisting of either surgical ligation17 or per-
cutaneous embolization (PVE) of the right portal vein with or without
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embolization of segment 4 portal branches,18 when the FLR volume
was considered inadequate. Threshold volumes for safe hepatectomy,
expressed as the FLR to TLV ratio, were more than 25% in patients
with normal liver and more than 30% in those who had received ex-
tensive chemotherapy, in those with prolonged cholestasis, in those
with severe fibrosis, or in those scheduled to undergo complex resec-
tions. In jaundiced patients, PVE was performed after percutaneous
decompression of the biliary tree on the side of the liver to be left in.
Surgery was then scheduled if sufficient hypertrophy of the FLR was
obtained 4 weeks after the procedure.10
For the purpose of this study, for each patient, we determined
the FLR volume, the tumor volume, and the TLV all in cm3. The tech-
nique of liver volumetry has been previously described.17,18 Briefly,
on axial CT images obtained during the portal venous phase after in-
travenous contrast injection, the hepatic total and segmental contours
of each slice were traced manually by a hepatobiliary radiologist. The
enclosed area was then determined automatically, and the volume
was calculated by summing each surface area multiplied by the slice
thickness. With the same procedure, the tumor volume was measured
in each patient. Half of the segment 4 volumewas included in the FLR
volume when liver resection was extended to either segment 4a or 4b.
The FRL volume was then equated to the TLV obtained by 2 different
methods as follows. The first method uses individual CT-measured
data and expresses the TLV, hereafter referred to as “measured total
liver volume” (mTLV), as the actual nontumorous TLV (mTLV [cm3]
= total CT-measured liver volume [cm3] − tumor volume [cm3]).
This is the method that has been routinely used at our institution
during the study period. The second method estimates the TLV, here-
after referred to as “estimated total liver volume” (eTLV), using a
mathematical formula derived from the linear correlation existing
between liver size and BSA (eTLV [cm3] = −794.41 + 1267.28 ×
BSA).9 BSA was calculated using weight and height according to the
Mosteller formula19: BSA = [weight (kg) × height (cm) ÷ 3600]1/2.
These 2 methods were compared using volumetric data in cm3, cor-
responding ratios expressed as percentages (measured ratio [mRatio]
= FLR in cm3/mTLV in cm3 × 100; estimated ratio [eRatio] = FLR
in cm3/eTLV in cm3 × 100), and clinical outcome measures, specif-
ically hepatic insufficiency and postoperative mortality, which was
defined as any death occurring within 90 days after surgery or within
the hospital stay during which the surgery was performed. Postop-
erative morbidity and mortality were reviewed on the basis of the
classification of Dindo et al.20 Complications of grade III or higher
were defined as major morbidity. Hepatic insufficiency was defined
as a peak postoperative serum total bilirubin level of more than 7.0
mg/dL4 or, in jaundiced patients, an increasing serum bilirubin con-
centration on postoperative day 5 or thereafter compared with the
values of the previous days.21 Hepatic insufficiency was considered a
major complication.
All statistical analyses were performed with SPSS (version
17.0; Chicago, IL). Variables are presented as absolute numbers and
percentage or median values and ranges. Statistical comparisons of
groups were performed with nonparametric tests, using the Mann-
Whitney U test for continuous variables and the χ 2 or Fisher exact
test for categorical data. Statistical significance was determined at
P < 0.05. All tests were 2-sided.
RESULTS
During the study period, of the 1305 hepatectomies, a total
of 485 noncirrhotic patients (37.2%) underwent resection of 3 or
more liver segments. In all, 243 patients met the inclusion criteria
and were enrolled in this study whereas the remaining 242 were
excluded because of unavailable anthropometric data (n = 135) or
CT scans (n = 107). There were 130 men and 113 women, with
a median age of 63 years. The demographic, anthropometric, and
clinical data of the study population are given in Table 1. More than
half of the patients (51.9%; n = 126) had a normal weight for their
height [body mass index (BMI) = 16.6–24.9 kg/m2], whereas the
remaining patients were overweight (BMI= 25–29.9 kg/m2) (36.6%;
n= 89) or obese (BMI≥30–49.8 kg/m2) (11.5%; n= 28). Indications
for resection were in most cases metastatic diseases (56.8%) from
colorectal (n = 124) or noncolorectal (n = 14) cancers, followed
by primary liver tumors (38.3%) of either hepatocellular or biliary
origin (hepatocellular carcinoma: n = 21; hilar cholangiocarcinoma:
n= 36; intrahepatic cholangiocarcinoma: n= 29; gallbladder cancer:
n = 7), and other diseases (4.9%; n = 12).
At the time of surgery, resection consisted of major hepa-
tectomies (ie, resection of 3 or 4 Couinaud segments) in 135 pa-
tients (55.6%) and in extended hepatectomies (ie, resection of 5 or
6 Couinaud segments) in 108 patients (44.4%). In addition to hep-
atic resection, 106 patients (43.6%) underwent 145 additional major
intra-abdominal procedures, including 9 vascular and 46 extrahepatic
bile duct resections. Preoperatively, 2 patients (9.5%) with hepa-
tocellular carcinoma underwent hepatic arterial chemoembolization
whereas 71 patients (57.2%) with colorectal liver metastases were
treated by systemic chemotherapy [median duration: 8 cycles (range:
4–18), with most patients (51/71; 71.8%) having received >6 cy-
cles]. One-hundred thirty patients (53.5%) experienced 1 or more
postoperative complications, which were classified as major, nonfatal
morbidities (Dindo grade III–IV) in 48 patients (19.7%). Postopera-
tive hepatic insufficiency occurred in 28 patients (11.5%). There were
TABLE 1. Descriptive Characteristics of the Study Cohort
Age, yr 63 (24–81)
Male:female ratio 130/113
ASA score (1/2/3/4) 10/95/92/43/3∗
Diabetes mellitus 29 (12.4%)∗
Body weight, kg 70 (39–144)
Body height, cm 165 (140–190)
BMI, kg/m2 24.93 (16.6–49.8)
BSA, m2 1.785 (1.287–2.608)








Extended right hepatectomies 58
Extended left hepatectomies 24
Right trisectionectomies ± S1 49
Left trisectionectomies ± S1 10
Other major hepatectomies 21
Additional major procedures




Target FLR safe volume
>25% 112
>30% 131
Preoperative PVO 44 (PVE: 39; PVL: 5)
Before major hepatectomy 9 (6%)
Before extended hepatectomy 35 (32.4%)
Values are expressed as absolute number (%) for categorical values or median
(range) for continuous ones.
∗Data not available for all patients.
ASA indicates American Society of Anesthesiologists; HA: hepatic artery; ICG,
indocyanine green; PV: portal vein; PVL, portal vein ligation.
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7 postoperative deaths, for a 90-day perioperative mortality rate of
2.9%. Of note, only one patient died of causes unrelated to the liver.
This was a 65-year-old woman who succumbed to an acute distress
respiratory syndrome on postoperative day 13. All other deaths were
associated with hepatic insufficiency. Although the other 22 patients
who developed hepatic insufficiency did not die, they endured a pro-
tracted recovery: median length of stay was 29.5 days (range: 8–90
days) versus 10 days (range: 5–127 days) in patients without postop-
erative hepatic insufficiency (P < 0.001).
Volumetric analysis revealed a significant difference between
mTLV (1375 cm3; range: 658–3081 cm3) and eTLV (1467 cm3; range:
837–2510 cm3) (P < 0.001). As shown in Figure 1, compared with
the eTLV, the mTLV underestimated the TLV in 60.1% of the cases,
whereas it was similar, within a difference of ±2.5%, in 11.1% of the
cases. In the remaining 28.8% of the patients, the mTLV was larger
than the eTLV. The volumetric difference between the 2 methods
was more pronounced in overweight and obese patients in whom it
reached statistical significance [mTLV vs eTLV in patients with BMI
<25 kg/m2 − 1265 cm3 vs 1308 cm3 (P= 0.125), with BMI 25–29.9
kg/m2 − 1421 cm3 vs 1578 cm3 (P< 0.001), andwith BMI≥30–49.8
kg/m2 − 1644 cm3 vs 1818 cm3 (P = 0.049)] (Fig. 2).
Forty-seven (19.3%) and 73 (30.0%) patients had an inade-
quate FLR based on the mRatio and the eRatio, respectively (P =
0.006). Preoperative PVO was used in 44 patients (18.1%) more
often—79.5% of the cases—before an extended hepatectomy. Analy-
sis of themTLVchanges after PVO (calculated as= [mTLVpost-PVO
−mTLVpre-PVO]/mTLVpre-PVO× 100), revealed that, overall, the
mTLV decreased by amedian of−3.7% (range:−37.6% to+27.8%),
from1373 cm3 (range: 852–2600 cm3) at baseline to 1350 cm3 (range:
824–2077 cm3) after PVO (P = 0.650) (Fig. 3). In particular, 17 pa-
tients (38.6%) had a reduction of the mTLV of more than 5% of its
initial value, 14 patients (31.8%) did not experience any significant
mTLV change (the mTLV remained within a range of more than−5%
to less than +5%), and 13 patients (29.6%) had an mTLV increase
of more than 5%. In patients with an overall reduction of the mTLV
after PVO, the risk was of overestimating the mRatio and thus under-
estimating the surgical risk. We observed that in the 17 patients who
had an mTLV reduction of more than 5%, the incidence of hepatic in-
sufficiency was higher than in those 27 in whom the mTLV remained
stable or increased (41.2% vs 18.5%). This difference, however, was
not statistically significant (P = 0.195) (Fig. 3). In addition, the 2
methods seemed similar in evaluating the degree of hypertrophy, de-
fined as the difference between the mRatio or the eRatio before and
after PVO.10 In particular, a degree of hypertrophy of more than
FIGURE 1. Scatter plots showing the correlation betweenmTLV
and eTLV. Dots correspond to individual patients.
FIGURE 2. Box plots of the mTLV and eTLV stratified by pa-
tient size. In each box, the horizontal line is the median; the
black square is the mean; the lower and upper borders are the
25th and 75th percentiles, respectively; and the lower and up-
per whiskers are the standard deviation. ∗Significant difference
(P < 0.05).
5% was observed in 37 patients (84.1%) using the mRatio and in 36
patients (81.8%) using the eRatio (P = 1.000).
To further investigate the utility of each method in predicting
a safe resection, the study cohort was stratified on the basis of con-
cordance/discordance in indicating the need for PVO. In 207 patients
(85.2%), the 2 methods were concordant in either indicating (n = 42)
or not indicating (n = 165) the opportunity to preoperatively stimu-
late the hypertrophy of the FLR. In these patients, PVO was used in
35 and 3 patients, respectively. In the remaining 36 patients (14.8%),
the 2 methods were discordant. In particular, in 5 patients, the mRatio
but not the eRatio suggested the need for PVO. In this subgroup, PVO
was used in 2 patients. In contrast, in the other 31 patients, the eRatio
but not the mRatio suggested the need for PVO, which was performed
in 4 patients. Figure 4 depicts the subgroups stratification. When
subgroups outcomes were analyzed, we observed that in patients in
whom PVOwas not indicated, whatever the method used and thus not
performed (n = 162), major complications occurred in 16.7% of the
patients, hepatic insufficiency in 4.9% of the patients, and postopera-
tive death in 0.6% of the patients. Conversely, in patients who would
have been subjected to PVO based on the eRatio who instead undergo
immediate surgery because of a safe mRatio (n= 27), the incidence of
major complications, hepatic insufficiency, and postoperative deaths
was higher (29.6%, P = 0.108; 22.2%, P = 0.001; and 3.7%,
P = 0.260, respectively). These results have been summarized in
Table 2. It is noteworthy that, among the 31 patients in whom the
eRatio but not the mRatio indicated the necessity of performing a
PVO, 18 (58.1%) had a BMI of less than 25 kg/m2, data that suggest
that in this subgroup as well, despite the failure to demonstrate a sig-
nificant difference in TLVs (Fig. 2), the use of the estimated method
(eTLV and eRatio) might be advantageous.
DISCUSSION
This study indicates that the use of the standardized liver
volumetry,8 a method based on the estimation of the TLV from the
patient’s BSA, identifies a not negligible subset of patients in whom
the traditional CT-based liver volumetry underestimates the risk of
postoperative hepatic insufficiency.
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FIGURE 3. Changes of the mTLV after PVO. A, Changes in cm3. B, Waterfall plot of the difference between post- and pre-PVO
expressed as a percentage of the initial volume. Each line represent individual patients with (dark gray) or without (light gray)
postoperative hepatic insufficiency.
FIGURE 4. Subgroup stratification of the study cohort based on the concordance/discordance of the 2 methods in indicating the
need for PVO.
In recent years, major and extended hepatectomies are being
used with increasing frequency to achieve complete tumor resection
in patients with hepatobiliary malignancies.2,3,7 Such extensive re-
sections, however, increase the risk of postoperative complications,
hepatic insufficiency, and mortality.4–6 On the basis of the associ-
ation between volume and function of the residual liver, it is be-
ing recognized that the preoperative determination of the FLR vol-
ume is critical to ensure that sufficient functional parenchyma re-
mains. However, although many have addressed the issue of defining
the lower volumetric limits for successful hepatectomies,11–14,22 the
clinical implications of the method used to measure liver volumes
have been rarely investigated. The traditional, most popular method
of liver volumetry entails the direct measurements on CT scan sets of
the total liver organ and segmental volumes. The FLR volume is then
equated to the nontumorous (ie, functional) TLV to calculate a ratio
that indicates the percentage of the TLV remaining after resection.
The efficacy of this method in discriminating patients at risk for hep-
atic insufficiency has been repeatedly proved.11,13,14,23 The present,
large, single-institution series, using validated and strict clinical pa-
rameters, including assessment of mortality at postoperative day 90,
reports low major morbidity and mortality rates. Such results further
validate this method of liver volumetry. Nevertheless, to measure
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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TABLE 2. Baseline Characteristics and Outcome of Patients
in Whom Both Methods of Liver Volumetry Did not Show
the Need for PVO and of Those in Whom Only the eRatio




eRatio (n = 162)
Necessary Only
Based on eRatio
(n = 27) P
Age, yr 63 (24–81) 65 (47–79) NS
Male sex 92 (56.8%) 13 (48.1%) NS
ASA score 3–4∗ 97 (59.9%) 13 (48.1%) NS
Diabetes mellitus∗ 23 (14.3%) 3 (11.1%) NS
BMI >25 kg/m2 86 (53.1%) 12 (44.4%) NS
ICG retention rate at 15 min∗ 3.9 (0.1–13.5) 3.1 (0.2–11.6) NS
Indications NS
Primary 57 (35.2%) 8 (29.6%)
Metastatic 96 (59.3%) 18 (66.7%)
Other 8 (5.5%) 1 (3.7%)
Extent of resection NS
Major hepatectomy 106 (65.4%) 16 (59.3%)
Extended hepatectomy 56 (34.6%) 11 (40.7%)
Associated resections 65 (40.1%) 9 (33.3%)
Morbidity 86 (53.1%) 13 (48.1%) NS
Major complications 27 (16.7%) 8 (29.6%) NS
Hepatic insufficiency 8 (4.9%) 6 (22.2%) 0.001
Mortality 1 (0.6%) 1 (3.7%) NS
Length of hospital stay, d 10 (5–127) 10 (6–90) NS
Values are expressed as absolute number (%) for categorical values or median
(range) for continuous ones.
∗Data not available for all patients.
ASA indicates American Society of Anesthesiologists; ICG, indocyanine green;
NS, not significant.
liver and tumor volumes, there are some disadvantages. Although er-
ror rates for measuring these volumes on CT scans have decreased to
less that 3%,24 in patients with multiple tumors, mathematical errors
cumulate because of multiple measurements. In addition, this method
relies on the assumption of a homogeneously preserved function of
the whole liver. This, however, is not always true. In patients with
segmental or sectorial biliary dilation or vascular obstruction, for ex-
ample, the compromised parenchyma reduces the actual functional
liver volume, which does not correspond to the actual TLV. Another
shortcoming is that this method does not provide a fixed estimation
for TLV before and after PVO; in patients experiencing a marked
atrophy of the embolized hemiliver, the use of a smaller post-PVO
denominator for calculating the eRatio will overestimate FLR hyper-
trophy. Consistently, in this series, we observed that in 38% of the
patients who had undergone PVO, at the reevaluation preceding re-
section, the mTLV was actually smaller, with a volume decrease of
more than 5% from the baseline. In such patients, the incidence of
hepatic insufficiency was 2-fold higher than that observed in all other
patients. This difference, however, did not reach statistical signifi-
cance probably because of the small sample size. Besides, the limited
number of patients also suggests caution in interpreting these data.
The last disadvantage of the traditional method of liver volumetry is
its possible inadequacy in patients selected for repeat hepatectomy
because liver regeneration after the first hepatectomy allows no more
than 85% of the original liver volume to be recovered.25
An alternativemethod, defined as standardized liver volumetry,
estimates the ideal TLV, using a formula developed on a large series of
patients undergoing CT for conditions unrelated to the hepatobiliary
system and based on the correlation existing between liver size and
BSA.9 The BSA is widely used as the biometric unit for normalizing
physiological parameters such as cardiac output, left ventricularmass,
or renal clearance and for determining the appropriate chemotherapy
drugs dosage in individuals of different body size. Estimating the
TLV with this BSA-based formula, which has been found to be the
most precise and unbiased equation among 12 existing models,26
corrects the actual liver volume to the individual patient’s size and
provides a validated, individualized estimate of that patient’s postre-
section liver function. In addition, this method overcomes most of the
shortcomings of the traditional method.
Whether remnant liver volume should be evaluated as a ratio
of FLR to mTLV or eTLV remains unknown. In this study, we sought
to determine which method of liver volumetry is more relevant in
assessing the minimum, safe FLR volume after major or extended
hepatectomy.We found that the eRatio allowed for better identification
of a subset of patients at risk for hepatic insufficiency. In particular,
in approximately 11% of our patients, we observed a discrepancy be-
tween the eRatio and the mRatio, with the mRatio falsely predicting a
safe resection. Interestingly, although significant differences in TLVs
were observed only in overweight or obese patients, differences in
corresponding ratios were uniformly distributed across the spectrum
of different body sizes, suggesting that the standardized liver vol-
umetry (eTLV and eRatio) might be advantageous in all patients. Yet,
if the eRatio were routinely used, we would have 1.5-fold increased
use of PVO. Robust evidence indicates that PVO is highly effective in
increasing the FLRmass preoperatively and that this hypertrophy sig-
nificantly reduces the risk of postoperative hepatic insufficiency. But
PVO causes adverse events in approximately 10% of the patients,10,27
and tumor progression after the procedure may occur.28–30 Therefore,
the clinical implication of expanding the number of candidates to
PVO will have to be carefully evaluated in the future studies. In par-
ticular, future studies should evaluate whether the reduction of hepatic
insufficiency will be counterbalanced by PVE-related adverse events.
This study suffers from the intrinsic limitations of any retro-
spective analysis. In addition, because we analyzed a selected pop-
ulation, having excluded some patients might infer a risk for bias.
However, we believe that meeting or not meeting our selection criteria
was just a matter of chance and that the risk for an unbiased selection
was minimum. Finally, the composition of our study cohort com-
prising disparate tumor types may have conditioned heterogeneous
outcomes because different cancer patients may be at a different risk.
Nonetheless, liver volumetry is a method established to assess the risk
of major or extended hepatectomy whatever the indication; different
threshold volumes for safe resection address the issue of different
levels of risk in different patients.
CONCLUSIONS
Weshowed that the use of the standardized volumetry identifies
a subset of patients in whom the traditional method of liver volumetry
significantly underestimates the risk of hepatic insufficiency. Because
of its numerous advantages, this method of liver volumetry should be
more widely adopted.
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DISCUSSANTS
P. Neuhaus (Germany):
That was an interesting talk. Let me say first that until today
I found it difficult to understand the usefulness of an estimated liver
volume based on BSA in comparison to CT-based volumetric calcu-
lation, which is, in fact, used in most hepatobiliary centers. Liver size
may vary considerably, and it is unclear why an estimation based on
BSA should be better than a seemingly more precise measurement. A
crucial question is assessment of liver function and prediction of liver
regeneration. With regard to liver function, the LiMAx test, which
will be soon available, is much superior to indocyanine green (ICG)
and other tests. However, for prediction of the regenerative capac-
ity of the FLR, we still do not have good tools, although we know
many things that might impair liver regeneration, for example, liver
pathologies such as sclerosis, age of the patient, and concomitant sep-
sis. Is it possible that your calculation of TLV in critically ill patients
with large fatty livers gives a considerably lower estimated volume
and a very low FLR volume? This would mean that patients with
oversized and poorly functioning livers might be excluded from re-
section. Another point is that besides your main outcome parameters
such as mortality, hepatic insufficiency, and major surgical complica-
tions, there are other factors such as extent of resection, blood loss,
postoperative liver function, age, biliary procedures, and so on, that
influence the outcome. From your article, I could see that you did
a univariate analysis, but do you have any data using multivariate
analysis? I thank you again for the presentation and the privilege to
comment.
Response From D. Ribero (Turin, Italy):
Professor Neuhaus, thank you very much for your thoughtful
comments. I will just go quickly through all of your questions. We
believe that using the estimated liver volume adds something in a
small group of patients, approximately 11% of the candidates for
major or extended liver resection. In this subgroup of patients, we
found 22% liver insufficiency. Thus,we need tomove forward because
we would like to avoid postoperative liver insufficiency.
It is difficult to exactly explain why the estimated liver volume
can be better than the measured liver volume. The estimation is based
on a formula that was derived from a large population of healthy
patients. On the basis of this, we could calculate the ideal liver volume
for an individual patient. We know that each patient may have an
enlarged liver or a shrunken liver because not all patients are equal.
With the estimated volume, we try to standardize the volume of the
liver to the patient size. We know that liver function is extremely
important in determining the outcome; however, there are many ways
to assess the function of the liver. The LiMAx test is certainly an
important test. We usually use the ICG test, which is well recognized.
The liver function in our patients was excellent, with a retention rate
of approximately 3.9. So, in patients who might be candidates for a
major or extended hepatectomy, beside the function, we need to find
something that helps define the surgical risk, and liver volume has
been shown to help in this risk assessment.
With regard to your last comment, obviously in surgery, we
have many components that might contribute to development of liver
insufficiency. However, before resection, we need a tool that should
be valuable in all patients, for any type of operation, and for any kind
of indication. Thank you.
DISCUSSANTS
F. Pruvot (Lille, France):
Congratulations on your article, one comment and one ques-
tion. Do you not think that comparison of measured and estimated
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TLV is an old story?We showed that the liver remnant to body weight
ratio is a more accurate method to calculate the risk of liver resection.
We published this in 2007 and presented this review in Helsinki in
2011. So, please could you recalculate your data with ratio to body
weight as a third method and send us the results; I am very interested.
My question is that you showed a particular subgroup with in-
creased morbidity, with decrease in TLV after portal vein emboliza-
tion. Was it because of atrophy of embolized liver or insufficient
hypertrophy of the remnant?
Response From D. Ribero (Turin, Italy):
I agree with your comment on FLR to body weight. We also
published before on this topic, andwhatwe have shown is that the FLR
to body weight was exactly the same as using FLR to the estimated
TLV. The problem in using the FLR to body weight is that those who
do not perform liver transplantation are not familiar with the results.
Most of the established cutoff points we showed are in percentages,
so people are more used to have percentages.
We do not know the reason for the liver shrinkage; we did not
look at each single-segment volume; however, the problem remains
in those patients in whom looking at the CT scan we had a significant
shrinkage of the right lobe rather than hypertrophy of the FLR. This
may be a problem because if we decrease the denominator, we might
overestimate the liver growth.
DISCUSSANTS
T. van Gulik (Amsterdam, The Netherlands):
Thank you, I enjoyed your article. I agree with you that the
estimated liver volume is attractive because it might correct the mis-
calculations in, for instance, vascular spaces and the tumor lobe. But
it is based on a normal population with normal livers and that is why
you excluded all the cirrhotic livers because you cannot apply it on
cirrhotic livers but you do apply it on patients who had combined
resections because of bile duct cancer. Those are the patients you
should also have included because they are not normal livers; they
are cholestatic livers or postcholestatic livers and therefore must skew
your results. So, I wonder how homogenous is the patient population
in order that you can use the estimated volume? Another point is that
it makes a difference if you use the formula in Asian population or
in European population. My final question is that you have done an
ICG clearance test in all patients but you have not used it in your
analysis in terms of determining patients who have an insufficient
liver functional reserve. Why is that?
Response From D. Ribero (Turin, Italy):
I will start with the last one. We used the ICG test in all
nonjaundiced patients when the bilirubin level was below 2 mg/dL,
and if you look at our results, the upper ICG limit at 15 minutes
was 13. There are data from the East that showed us that in cirrhotic
patients, we could also do major hepatectomy in patients with ICG
limits up to 14; so, we think that liver function was good. I do not
completely agree with you about patients with jaundice; of course, if
you measure the volume in a jaundiced patient, this might be enlarged
because of the dilation of the biliary tree. But this is a patient with
basically a normal liver, or at least noncirrhotic. So with the formula,
we estimate the theoretical volume that the patient would require; it
does not matter if now the patient has an enlarged liver because of
the jaundice, which might have lasted for the past couple of weeks.
On the contrary, I agree with you that we need to look more closely
at cirrhotic patients.
DISCUSSANTS
C.H.C. Dejong (Maastricht, The Netherlands):
You have a median BMI of 25, so half are above and half are
below this BMI. This is another confounding factor because there
are patients who are obese and yet sarcopenic. You can measure the
volume of themuscle at the L3 level, and theymay regenerate less and
they may have less functional recovery. I think you should be invited
to look more closely at the level of sarcopenia in these patients, even
the obese patients.
C.M. Lo (Hong Kong, PR China):
I like your conclusion because I have used estimated liver
volume, but I do not think your data can support the conclusion.
Your data are basically supported by the 27 patients in whom the
estimated TLV would indicate a need for portal vein embolization
and you end up with 6 having liver insufficiency. But your defini-
tion of hepatic insufficiency is only based on jaundice, where you
have patients who have bile duct resection as well. There are many
reasons that patients can have jaundice after hepatic resection, par-
ticularly when you do bile duct resection and other procedures, in-
fection, etc. So, basing your conclusion on 6 of 27 patients with
hepatic insufficiency is very flimsy, and I think you may have to re-
consider your definition for liver insufficiency and look into these 6
patients.
Response From D. Ribero (Turin, Italy):
The problem of the definition of liver insufficiency is always
a major issue and what we did was just to use the established cri-
teria that have been published after a consensus of expert liver sur-
geons; using an established definition of liver insufficiency is the
only way we have to compare studies. But still, this definition re-
mains a problem. About the cachexia, we do not operate cachectic
patients.
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